Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

3(42.9%)

Phase 1

1(14.3%)

7Total

Phase 2(3)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05594563Phase 2Recruiting

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

Role: collaborator

NCT01349881Phase 3Active Not Recruiting

S0820, Adenoma and Second Primary Prevention Trial

Role: collaborator

NCT02794428Phase 2Completed

Chemoprevention of Gastric Carcinogenesis

Role: collaborator

NCT01059071Phase 1Completed

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Role: collaborator

NCT01483144Phase 3Completed

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Role: lead

NCT01245816Phase 3Withdrawn

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Role: lead

NCT01636128Phase 2Withdrawn

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Role: lead

All 7 trials loaded